Abstract: The present disclosure relates to a method for preparing killed lactic acid bacteria using a bioreactor including a culture device and a membrane filter, and to killed lactic acid bacteria prepared by the preparation method.

Abstract: A composition for the treatment of atopic dermatitis, the composition including, as an active ingredient, Bifidobacterium animalis subsp. lactis LM1017, and more specifically provided is a composition for the treatment of atopic dermatitis. The composition includes, as an active ingredient, a navel Bifidobacterium animalis subsp. lactis LM1017 which adjusts the NF-?B signal transduction pathway, and thus inhibits the expression of proinflammatory cytokines.

Abstract: The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus. The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.

Abstract: The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

Abstract: The present disclosure relates to a novel strain of Lactobacillus fermentum LM1016 (KCCM12468P). The disclosed strain can be useful for treating or preventing cardiovascular diseases, obesity, fatty liver and/or diabetes. The present disclosure also relates to compositions comprising the strain. The compositions can be useful for medicines, health-functional foods, dairy products, fermented products, food additives, animal feeds, etc.

Abstract: The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.